1.53
+0.11(+7.75%)
Currency In USD
Address
Zeus Building
Didcot, OX11 0DF
United Kingdom of Great Britain and Northern Ireland
Phone
44 1865 818 808
Website
Sector
Healthcare
Industry
Biotechnology
Employees
105
First IPO Date
April 30, 2021
| Name | Title | Pay | Year Born |
| Mr. William J. Enright MBA | Chief Executive Officer, Director & Principal Financial Officer | 986,386 | 1962 |
| Ms. Sarah Gilbert | Co-Founder | 48,983 | N/A |
| Mr. Adrian Hill Ph.D. | Co-Founder & Scientific Advisor | 61,606 | N/A |
| Ms. Gemma Brown | Principal Accounting Officer | 501,415 | 1990 |
| Mr. Graham Griffiths | Chief Operating Officer | 593,280 | 1980 |
| Dr. Geoffrey Lynn M.D., Ph.D. | Chief Scientific Officer | 0 | 1985 |
| Dr. Leon Hooftman M.D. | Chief Medical Officer | 0 | 1958 |
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Harwell, the United Kingdom.